SUPPLEMENTARY MATERIAL

Supplement 1: Additional Tables and Figures

SUPPLEMENTARY TABLE 1 ARIA and macrohemorrhage by *APOE* ε4 genotype at 18 months.

	Aducanumab (N=69)			**Donanemab (N=71)**		
	***APOE* ε4 genotype**					
Event n (%)	**Noncarrier (N=20)**	**Heterozygote (N=39)**	**Homozygote (N=10)**	**Noncarrier (N=22)**	**Heterozygote (N=40)**	**Homozygote (N=9)**
ARIA-E or ARIA-H*	7 (35.0)	14 (35.9)	7 (70.0)	3 (13.6)	14 (35.0)	4 (44.4)
ARIA-E*	5 (25.0)	12 (30.8)	7 (70.0)	2 (9.1)	11 (27.5)	4 (44.4)
Symptomatic	1 (5.0)	2 (5.1)	2 (20.0)	0 (0.0)	2 (5.0)	0 (0.0)
SAE†	1 (5.0)	1 (2.6)	0 (0.0)	1 (4.5)	0 (0.0)	0 (0.0)
ARIA-H*,‡,§	5 (25.0)	13 (33.3)	5 (50.0)	2 (9.1)	10 (25.0)	4 (44.4)
Symptomatic*,‡	1 (5.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.5)	0 (0.0)
Macrohemorrhage*,§	0 (0.0)	1 (2.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

* Based on MRI or TEAE cluster; † Based on TEAE cluster; ‡ ARIA-H includes microhemorrhage and superficial siderosis;

§ There were no SAE cases for ARIA-H or macrohemorrhage.

Abbreviations: *APOE*, apolipoprotein E; ARIA-E, amyloid-related imaging abnormalities of edema/effusion; ARIA-H, amyloid-related imaging abnormalities of microhemorrhage and hemosiderin deposits; MRI, magnetic resonance imaging; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

SUPPLEMENTARY FIGURE 1 Donanemab and aducanumab treatment demonstrated changes in plasma biomarkers of (A) GFAP, (B) P-tau217, (C) P-tau181, and (D) NfL at 6, 12, and 18 months in the low-medium tau subpopulation.



Data are shown as LSM (standard error). *P*-value represents treatment difference of donanemab vs aducanumab.

Abbreviations: GFAP, glial fibrillary acidic protein; LSM, least-squares mean; n, number of participants; NfL, neurofilament light chain; P-tau217, phosphorylated tau 217; P-tau181, phosphorylated tau 181.